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Abstract
The mandible is a rare site for the occurrence of primary bone lymphoma (PBL), a non-Hodgkin
lymphoma. We report herein a case of an incidentally diagnosed thyroid incidentaloma by
18Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in a patient with a
previous diagnosis of PBL. Therapeutic options are reviewed and discussed.
Introduction
Primary bone lymphoma (PBL) represents approximately
3% of all malignant bone tumors [1] and 5% of all non-
Hodgkin lymphomas. Most occurrences present similar
characteristics such as a slightly greater frequency in men,
early-stage disease presentation and a median age of
appearance in the fifth or sixth decade. PBL can appear in
any part of the skeleton. The most common tumor sites are
the long bones (50% extremities), followed by the axial
skeleton (44%). The mandible is a rare location, compris-
ing approximately only 2-4% of all PBLs [2,3].
Establishment of useful diagnostic and therapeutic guide-
lines is problematic because of the infrequency of PBLs.
PBL therapy has evolved from radiotherapy as a stand-
alone strategy (since the 1960s) to combined modality
therapy (chemotherapy and radiotherapy) [4]. There have
also been a few reports of patients treated with chemother-
apy alone [2,3]. Surgery is currently limited to diagnostic
procedures and repair of pathological fractures of the bone.
Diffuse large B-cell lymphoma (DLBCL) is the most
frequent histopathological subtype of PBL. Standard
chemotherapy for patients with DLBCL consists of
administration of CHOP (cyclophosphamide, doxorubi-
cin, vincristine, and prednisone) in conjunction with the
monoclonal antiCD20 rituximab [5-7]. Treatment options
differ for patients with localized (Ann Arbor stage I-II) or
advanced (Ann Arbor stage III-IV) disease. We present the
case of a PBL that affected the mandible. Therapeutic
options are reviewed and discussed.
Case presentation
A 47-year-old Caucasian Spanish man presented with a
history of eight months of dental pain. Despite extraction of
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two teeth (numbers 37 and 38), improvement of symptoms
was not achieved. A computed tomography (CT) scan of the
head revealed an osteolytic lesion on the left mandible of
3.8 ¥ 1 cm (Figure 1). A CT-guided biopsy was performed.
Histopathological examination of the biopsy revealed a
DLBCL; immunohistochemistry analysis tested positive for
cytoplasmic CD20, Bcl-2 and nuclear Bcl-6.
The disease was staged using a bone marrow biopsy, CT
body scan and fluorodeoxyglucose positron emission
tomography (FDG PET). CT scan revealed a lesion on
the left mandible as well as the presence of a cyst on the
right thyroid. 18FDG PET/CT showed high uptake of tracer
in the left mandible lesion with a standard uptake value
(SUV) of 5.5 (Figure 1) and a higher focal uptake in the
right thyroid, with an SUV of 8 (Figure 2). The bone
marrow biopsy and hematological and chemical analysis
were normal. A fine-needle aspiration (FNA) guided by
echography of the thyroid lesion revealed a papillary
thyroid carcinoma.
Figure 1. 18FDG PET/CT showing the left mandible lesion in sagital (a), coronal (b) and axial (d) view. Image (c) shows an
osteolytic lesion in the left mandible in an axial view of the CT scan.
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The final diagnosis was DLBCL stage I EA with a low IPI
score and a synchronic papillary thyroid carcinoma.
The papillary thyroid carcinoma was treated first with a
total thyroidectomy. Anatomopathological examination
revealed a follicular variant of papillary carcinoma of the
thyroid of 1.5 cm with pT1pN1aM0 stage (stage III). The
patient began treatment with levothyroxine.
The lymphoma was treated with six cycles of chemother-
apy (R-CHOP) with good tolerance. An 18FDG PET/CT
was performed at the end of the treatment with no
pathological signal.
After chemotherapy the patient was irradiated with 3D
conformational radiotherapy. The left mandible branch
received 30 Gy in 20 fractions of 2.0 Gy followed by 6 Gy
as a boost to the initial tumor volume.
One month later, the patient received adjuvant radio-
iodine ablation with I131 for the thyroid carcinoma. The
patient has been completely tumor-free of the two tumors
for 28 months, with the last follow-up in January 2009.
Discussion
Presentation symptoms of PBL include localized bone
pain and sometimes the presence of a palpable mass. In
Figure 2. 18FDG PET/CT showing the thyroid incidentaloma in sagital (a), coronal (b) and axial (d) view. Image (c) shows
the right thyroid cyst on the CT scan.
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the mandible, the main symptoms of PBL are pain,
swelling, numbness, tooth mobility and cervical lympha-
denopathy. In this case, the patient had what appeared to
be dental caries, which were previously evaluated by a
dentist. Initial diagnosis is often wrong; Limb et al.
suggested that the mean time to achieve a correct diagnosis
of PBL is 8 months [1].
The role of FDG-PET in the management of patients with
lymphoma is clear. It has the potential to influence both
the initial choice of chemotherapy and alterations to the
management of the disease based on the response to
therapy [8]. In our case, the 18FDG PET/CT provided
staging information of the lymphoma and revealed the
presence of a hypermetabolic lesion on the thyroid that
was finally diagnosed as papillary carcinoma.
Thyroid incidentalomas are defined as newly identified
thyroid lesions encountered during imaging studies. As
18FDG PET/CT is becoming a more common imaging
modality, the incidence of thyroid incidentalomas is also
increasing. A few retrospective studies have shown the
prevalence of this finding to be approximately 2.3% [9].
Kang et al. studied the possibility of differentiating a
malignant from a benign lesion with SUV.While a SUV > 9
suggested a higher likelihood of cancer, the authors
concluded that a pathological confirmation is required.
The value of FDG-PET in patients with differentiated
thyroid cancer is under review. FDG-PET has a clear role
in I131-negative thyroid cancer and follow-up, but it
should not be performed in patients with a stimulated
Tg < 10 μgr/L because of its low sensitivity [10,11].
The treatment and optimal management of patients with
PBL are unclear because of the low incidence of this
pathology. Few retrospective studies have examined the
clinical characteristics, treatment and outcome of these
patients. The published studies span many years, during
which time staging techniques and treatment modalities
have changed. Despite the heterogeneity of the treatment
in the literature, it seems clear that a combined modality
therapy of chemotherapy with radiotherapy leads to better
results than a single modality of treatment [2,12]. Someya
et al. reviewed the literature regarding the treatment of PBL
of the mandible and concluded that radiotherapy alone
was not enough for tumor control for stage I + II disease
and that combination chemotherapy might be needed
[13]. This conclusion is consistent with the results of
studies on patients with early-stage non-Hodgkin
lymphoma [14,15].
Rituximab added to six cycles of CHOP is an effective
treatment for young patients with good-prognosis DLBCL
[7] and is currently the gold standard treatment for these
patients. This regimen results in improvement of both
event-free survival and survival. The excellent results
achieved in patients with stage I without bulky disease
suggest that the addition of rituximab may lead to a
reduction in chemotherapy cycles and may therefore be an
option for the future treatment of these patients.
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